市場調査レポート
商品コード
1377754

関節リウマチ治療薬の世界市場 2024-2028

Global Rheumatoid Arthritis Drugs Market 2024-2028

出版日: | 発行: TechNavio | ページ情報: 英文 162 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
関節リウマチ治療薬の世界市場 2024-2028
出版日: 2023年10月30日
発行: TechNavio
ページ情報: 英文 162 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

関節リウマチ治療薬市場は、2023年から2028年にかけて160億4,512万米ドル、予測期間中のCAGRは7.5%で成長すると予測されています。

当レポートでは、関節リウマチ治療薬市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。関節リウマチ(RA)の症例の増加、リウマチ専門医の増加、診断方法の改善、RAに対する手頃な価格の生物学的製剤の必要性などが市場を牽引しています。

市場範囲
基準年 2023
終了年 2028
予測期間 2024-2028
成長モメンタム 加速
前年比2024年 6.4%
CAGR 7.5%
増分額 160億4,512万米ドル

当レポートでは、今後数年間の関節リウマチ治療薬市場成長を牽引する主要因の1つとして、RAに対する医療保険制度の提供を挙げています。また、RA治療における生物学的製剤/バイオシミラーの使用やRA治療における遺伝子治療の使用は、市場の大きな需要につながります。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場エコシステム

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 2023
  • 市場の見通し 2023-2028

第4章 市場規模実績

  • 関節リウマチ治療薬の世界市場 2018-2022
  • 薬剤クラス別セグメント分析 2018-2022
  • タイプ別セグメント分析 2018-2022
  • 地域別セグメント分析 2018-2022
  • 国別セグメント分析 2018-2022

第5章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第6章 市場セグメンテーション:薬剤クラス別

  • 市場セグメント
  • 比較:薬剤クラス別
  • 疾患修飾性抗リウマチ薬:市場規模と予測 2023-2028
  • 非ステロイド性抗炎症薬:市場規模と予測 2023-2028
  • コルチコステロイド:市場規模と予測 2023-2028
  • 市場機会:薬剤クラス別

第7章 市場セグメンテーション:タイプ別

  • 市場セグメント
  • 比較:タイプ別
  • 生物製剤:市場規模と予測 2023-2028
  • 低分子:市場規模と予測 2023-2028
  • 市場機会:タイプ別

第8章 顧客情勢

  • 顧客情勢の概要

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米:市場規模と予測 2023-2028
  • 欧州:市場規模と予測 2023-2028
  • アジア:市場規模と予測 2023-2028
  • 世界のその他の地域:市場規模と予測 2023-2028
  • 米国:市場規模と予測 2023-2028
  • 英国:市場規模と予測 2023-2028
  • 中国:市場規模と予測 2023-2028
  • ドイツ:市場規模と予測 2023-2028
  • フランス:市場規模と予測 2023-2028
  • 市場機会:地域情勢別

第10章 促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 促進要因と課題の影響
  • 市場動向

第11章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Genor Biopharma Holdings Ltd.
  • Gilead Sciences Inc.
  • Johnson and Johnson
  • Kangstem Biotech Co. Ltd.
  • Novartis AG
  • Oryn Therapeutics
  • Pfizer Inc.
  • Sanofi
  • Sorrento Therapeutics Inc.
  • UCB SA

第13章 付録

図表

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Drug Class
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Type
  • Exhibits7: Executive Summary - Chart on Incremental Growth
  • Exhibits8: Executive Summary - Data Table on Incremental Growth
  • Exhibits9: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits10: Parent market
  • Exhibits11: Market Characteristics
  • Exhibits12: Offerings of vendors included in the market definition
  • Exhibits13: Market segments
  • Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million)
  • Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
  • Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibits18: Historic Market Size - Data Table on global rheumatoid arthritis drugs market 2018 - 2022 ($ million)
  • Exhibits19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
  • Exhibits20: Historic Market Size - Type Segment 2018 - 2022 ($ million)
  • Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
  • Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
  • Exhibits23: Five forces analysis - Comparison between 2023 and 2028
  • Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
  • Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
  • Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
  • Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
  • Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
  • Exhibits29: Chart on Market condition - Five forces 2023 and 2028
  • Exhibits30: Chart on Drug Class - Market share 2023-2028 (%)
  • Exhibits31: Data Table on Drug Class - Market share 2023-2028 (%)
  • Exhibits32: Chart on Comparison by Drug Class
  • Exhibits33: Data Table on Comparison by Drug Class
  • Exhibits34: Chart on Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028 ($ million)
  • Exhibits35: Data Table on Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028 ($ million)
  • Exhibits36: Chart on Disease-modifying anti-rheumatic drugs - Year-over-year growth 2023-2028 (%)
  • Exhibits37: Data Table on Disease-modifying anti-rheumatic drugs - Year-over-year growth 2023-2028 (%)
  • Exhibits38: Chart on Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028 ($ million)
  • Exhibits39: Data Table on Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028 ($ million)
  • Exhibits40: Chart on Nonsteroidal anti-inflammatory drugs - Year-over-year growth 2023-2028 (%)
  • Exhibits41: Data Table on Nonsteroidal anti-inflammatory drugs - Year-over-year growth 2023-2028 (%)
  • Exhibits42: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
  • Exhibits43: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
  • Exhibits44: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
  • Exhibits45: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
  • Exhibits46: Market opportunity by Drug Class ($ million)
  • Exhibits47: Data Table on Market opportunity by Drug Class ($ million)
  • Exhibits48: Chart on Type - Market share 2023-2028 (%)
  • Exhibits49: Data Table on Type - Market share 2023-2028 (%)
  • Exhibits50: Chart on Comparison by Type
  • Exhibits51: Data Table on Comparison by Type
  • Exhibits52: Chart on Biologics - Market size and forecast 2023-2028 ($ million)
  • Exhibits53: Data Table on Biologics - Market size and forecast 2023-2028 ($ million)
  • Exhibits54: Chart on Biologics - Year-over-year growth 2023-2028 (%)
  • Exhibits55: Data Table on Biologics - Year-over-year growth 2023-2028 (%)
  • Exhibits56: Chart on Small Molecules - Market size and forecast 2023-2028 ($ million)
  • Exhibits57: Data Table on Small Molecules - Market size and forecast 2023-2028 ($ million)
  • Exhibits58: Chart on Small Molecules - Year-over-year growth 2023-2028 (%)
  • Exhibits59: Data Table on Small Molecules - Year-over-year growth 2023-2028 (%)
  • Exhibits60: Market opportunity by Type ($ million)
  • Exhibits61: Data Table on Market opportunity by Type ($ million)
  • Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits63: Chart on Market share By Geographical Landscape 2023-2028 (%)
  • Exhibits64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
  • Exhibits65: Chart on Geographic comparison
  • Exhibits66: Data Table on Geographic comparison
  • Exhibits67: Chart on North America - Market size and forecast 2023-2028 ($ million)
  • Exhibits68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
  • Exhibits69: Chart on North America - Year-over-year growth 2023-2028 (%)
  • Exhibits70: Data Table on North America - Year-over-year growth 2023-2028 (%)
  • Exhibits71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
  • Exhibits72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
  • Exhibits73: Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibits74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibits75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
  • Exhibits76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
  • Exhibits77: Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibits78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibits83: Chart on US - Market size and forecast 2023-2028 ($ million)
  • Exhibits84: Data Table on US - Market size and forecast 2023-2028 ($ million)
  • Exhibits85: Chart on US - Year-over-year growth 2023-2028 (%)
  • Exhibits86: Data Table on US - Year-over-year growth 2023-2028 (%)
  • Exhibits87: Chart on UK - Market size and forecast 2023-2028 ($ million)
  • Exhibits88: Data Table on UK - Market size and forecast 2023-2028 ($ million)
  • Exhibits89: Chart on UK - Year-over-year growth 2023-2028 (%)
  • Exhibits90: Data Table on UK - Year-over-year growth 2023-2028 (%)
  • Exhibits91: Chart on China - Market size and forecast 2023-2028 ($ million)
  • Exhibits92: Data Table on China - Market size and forecast 2023-2028 ($ million)
  • Exhibits93: Chart on China - Year-over-year growth 2023-2028 (%)
  • Exhibits94: Data Table on China - Year-over-year growth 2023-2028 (%)
  • Exhibits95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
  • Exhibits96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
  • Exhibits97: Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibits98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibits99: Chart on France - Market size and forecast 2023-2028 ($ million)
  • Exhibits100: Data Table on France - Market size and forecast 2023-2028 ($ million)
  • Exhibits101: Chart on France - Year-over-year growth 2023-2028 (%)
  • Exhibits102: Data Table on France - Year-over-year growth 2023-2028 (%)
  • Exhibits103: Market opportunity By Geographical Landscape ($ million)
  • Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million)
  • Exhibits105: Impact of drivers and challenges in 2023 and 2028
  • Exhibits106: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits107: Overview on factors of disruption
  • Exhibits108: Impact of key risks on business
  • Exhibits109: Vendors covered
  • Exhibits110: Matrix on vendor position and classification
  • Exhibits111: AbbVie Inc. - Overview
  • Exhibits112: AbbVie Inc. - Product / Service
  • Exhibits113: AbbVie Inc. - Key news
  • Exhibits114: AbbVie Inc. - Key offerings
  • Exhibits115: Amgen Inc. - Overview
  • Exhibits116: Amgen Inc. - Product / Service
  • Exhibits117: Amgen Inc. - Key offerings
  • Exhibits118: Bristol Myers Squibb Co. - Overview
  • Exhibits119: Bristol Myers Squibb Co. - Product / Service
  • Exhibits120: Bristol Myers Squibb Co. - Key news
  • Exhibits121: Bristol Myers Squibb Co. - Key offerings
  • Exhibits122: Eli Lilly and Co. - Overview
  • Exhibits123: Eli Lilly and Co. - Product / Service
  • Exhibits124: Eli Lilly and Co. - Key news
  • Exhibits125: Eli Lilly and Co. - Key offerings
  • Exhibits126: F. Hoffmann La Roche Ltd. - Overview
  • Exhibits127: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibits128: F. Hoffmann La Roche Ltd. - Key news
  • Exhibits129: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibits130: F. Hoffmann La Roche Ltd. - Segment focus
  • Exhibits131: Genor Biopharma Holdings Ltd. - Overview
  • Exhibits132: Genor Biopharma Holdings Ltd. - Product / Service
  • Exhibits133: Genor Biopharma Holdings Ltd. - Key offerings
  • Exhibits134: Gilead Sciences Inc. - Overview
  • Exhibits135: Gilead Sciences Inc. - Product / Service
  • Exhibits136: Gilead Sciences Inc. - Key news
  • Exhibits137: Gilead Sciences Inc. - Key offerings
  • Exhibits138: Johnson and Johnson - Overview
  • Exhibits139: Johnson and Johnson - Business segments
  • Exhibits140: Johnson and Johnson - Key news
  • Exhibits141: Johnson and Johnson - Key offerings
  • Exhibits142: Johnson and Johnson - Segment focus
  • Exhibits143: Kangstem Biotech Co. Ltd. - Overview
  • Exhibits144: Kangstem Biotech Co. Ltd. - Product / Service
  • Exhibits145: Kangstem Biotech Co. Ltd. - Key offerings
  • Exhibits146: Novartis AG - Overview
  • Exhibits147: Novartis AG - Business segments
  • Exhibits148: Novartis AG - Key offerings
  • Exhibits149: Novartis AG - Segment focus
  • Exhibits150: Oryn Therapeutics - Overview
  • Exhibits151: Oryn Therapeutics - Product / Service
  • Exhibits152: Oryn Therapeutics - Key offerings
  • Exhibits153: Pfizer Inc. - Overview
  • Exhibits154: Pfizer Inc. - Product / Service
  • Exhibits155: Pfizer Inc. - Key news
  • Exhibits156: Pfizer Inc. - Key offerings
  • Exhibits157: Sanofi - Overview
  • Exhibits158: Sanofi - Business segments
  • Exhibits159: Sanofi - Key news
  • Exhibits160: Sanofi - Key offerings
  • Exhibits161: Sanofi - Segment focus
  • Exhibits162: Sorrento Therapeutics Inc. - Overview
  • Exhibits163: Sorrento Therapeutics Inc. - Business segments
  • Exhibits164: Sorrento Therapeutics Inc. - Key offerings
  • Exhibits165: Sorrento Therapeutics Inc. - Segment focus
  • Exhibits166: UCB SA - Overview
  • Exhibits167: UCB SA - Product / Service
  • Exhibits168: UCB SA - Key offerings
  • Exhibits169: Inclusions checklist
  • Exhibits170: Exclusions checklist
  • Exhibits171: Currency conversion rates for US$
  • Exhibits172: Research methodology
  • Exhibits173: Validation techniques employed for market sizing
  • Exhibits174: Information sources
  • Exhibits175: List of abbreviations
目次
Product Code: IRTNTR73313

Abstract

The rheumatoid arthritis drugs market is forecasted to grow by USD 16045.12 mn during 2023-2028, accelerating at a CAGR of 7.5% during the forecast period. The report on the rheumatoid arthritis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising cases of RA and focus on increasing number of rheumatologists, availability of improved diagnostic modalities, and need for affordable biologics for RA.

Market Scope
Base Year2023
End Year2028
Series Year2024-2028
Growth MomentumAccelerate
YOY 20246.4%
CAGR7.5%
Incremental Value$16045.12mn

Technavio's rheumatoid arthritis drugs market is segmented as below:

By Drug Class

  • Disease-modifying anti-rheumatic drugs
  • Nonsteroidal anti-inflammatory drugs
  • Corticosteroids

By Type

  • Biologics
  • Small Molecules

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the health plan offerings for RA as one of the prime reasons driving the rheumatoid arthritis drugs market growth during the next few years. Also, use of biologics/biosimilars for treatment of RA and use of gene therapy for RA treatment will lead to sizable demand in the market.

The report on the rheumatoid arthritis drugs market covers the following areas:

  • Rheumatoid arthritis drugs market sizing
  • Rheumatoid arthritis drugs market forecast
  • Rheumatoid arthritis drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading rheumatoid arthritis drugs market vendors that include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galmed Pharmaceuticals Ltd., Genor Biopharma Holdings Ltd., Gilde Healthcare, Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Kangstem Biotech Co. Ltd., Novartis AG, Oryn Therapeutics, Pfizer Inc., Sanofi, Sorrento Therapeutics Inc., Taisho Pharmaceutical Holdings Co. Ltd., and UCB SA. Also, the rheumatoid arthritis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2023
  • 3.4 Market outlook: Forecast for 2023-2028
  • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

  • 4.1 Global rheumatoid arthritis drugs market 2018 - 2022
  • Exhibit 18: Historic Market Size - Data Table on global rheumatoid arthritis drugs market 2018 - 2022 ($ million)
  • 4.2 Drug Class Segment Analysis 2018 - 2022
  • Exhibit 19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
  • 4.3 Type Segment Analysis 2018 - 2022
  • Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ million)
  • 4.4 Geography Segment Analysis 2018 - 2022
  • Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
  • 4.5 Country Segment Analysis 2018 - 2022
  • Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Drug Class

  • 6.1 Market segments
  • Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%)
  • Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%)
  • 6.2 Comparison by Drug Class
  • Exhibit 32: Chart on Comparison by Drug Class
  • Exhibit 33: Data Table on Comparison by Drug Class
  • 6.3 Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028
  • Exhibit 34: Chart on Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028 ($ million)
  • Exhibit 35: Data Table on Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028 ($ million)
  • Exhibit 36: Chart on Disease-modifying anti-rheumatic drugs - Year-over-year growth 2023-2028 (%)
  • Exhibit 37: Data Table on Disease-modifying anti-rheumatic drugs - Year-over-year growth 2023-2028 (%)
  • 6.4 Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028
  • Exhibit 38: Chart on Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028 ($ million)
  • Exhibit 39: Data Table on Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028 ($ million)
  • Exhibit 40: Chart on Nonsteroidal anti-inflammatory drugs - Year-over-year growth 2023-2028 (%)
  • Exhibit 41: Data Table on Nonsteroidal anti-inflammatory drugs - Year-over-year growth 2023-2028 (%)
  • 6.5 Corticosteroids - Market size and forecast 2023-2028
  • Exhibit 42: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
  • Exhibit 43: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
  • Exhibit 44: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
  • Exhibit 45: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
  • 6.6 Market opportunity by Drug Class
  • Exhibit 46: Market opportunity by Drug Class ($ million)
  • Exhibit 47: Data Table on Market opportunity by Drug Class ($ million)

7 Market Segmentation by Type

  • 7.1 Market segments
  • Exhibit 48: Chart on Type - Market share 2023-2028 (%)
  • Exhibit 49: Data Table on Type - Market share 2023-2028 (%)
  • 7.2 Comparison by Type
  • Exhibit 50: Chart on Comparison by Type
  • Exhibit 51: Data Table on Comparison by Type
  • 7.3 Biologics - Market size and forecast 2023-2028
  • Exhibit 52: Chart on Biologics - Market size and forecast 2023-2028 ($ million)
  • Exhibit 53: Data Table on Biologics - Market size and forecast 2023-2028 ($ million)
  • Exhibit 54: Chart on Biologics - Year-over-year growth 2023-2028 (%)
  • Exhibit 55: Data Table on Biologics - Year-over-year growth 2023-2028 (%)
  • 7.4 Small Molecules - Market size and forecast 2023-2028
  • Exhibit 56: Chart on Small Molecules - Market size and forecast 2023-2028 ($ million)
  • Exhibit 57: Data Table on Small Molecules - Market size and forecast 2023-2028 ($ million)
  • Exhibit 58: Chart on Small Molecules - Year-over-year growth 2023-2028 (%)
  • Exhibit 59: Data Table on Small Molecules - Year-over-year growth 2023-2028 (%)
  • 7.5 Market opportunity by Type
  • Exhibit 60: Market opportunity by Type ($ million)
  • Exhibit 61: Data Table on Market opportunity by Type ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
  • Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
  • 9.2 Geographic comparison
  • Exhibit 65: Chart on Geographic comparison
  • Exhibit 66: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2023-2028
  • Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
  • Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
  • Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
  • Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
  • 9.4 Europe - Market size and forecast 2023-2028
  • Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
  • Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
  • Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
  • 9.5 Asia - Market size and forecast 2023-2028
  • Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
  • Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
  • Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
  • Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • 9.7 US - Market size and forecast 2023-2028
  • Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
  • Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
  • Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
  • Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
  • 9.8 UK - Market size and forecast 2023-2028
  • Exhibit 87: Chart on UK - Market size and forecast 2023-2028 ($ million)
  • Exhibit 88: Data Table on UK - Market size and forecast 2023-2028 ($ million)
  • Exhibit 89: Chart on UK - Year-over-year growth 2023-2028 (%)
  • Exhibit 90: Data Table on UK - Year-over-year growth 2023-2028 (%)
  • 9.9 China - Market size and forecast 2023-2028
  • Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ million)
  • Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ million)
  • Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
  • Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
  • 9.10 Germany - Market size and forecast 2023-2028
  • Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
  • Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
  • Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
  • 9.11 France - Market size and forecast 2023-2028
  • Exhibit 99: Chart on France - Market size and forecast 2023-2028 ($ million)
  • Exhibit 100: Data Table on France - Market size and forecast 2023-2028 ($ million)
  • Exhibit 101: Chart on France - Year-over-year growth 2023-2028 (%)
  • Exhibit 102: Data Table on France - Year-over-year growth 2023-2028 (%)
  • 9.12 Market opportunity By Geographical Landscape
  • Exhibit 103: Market opportunity By Geographical Landscape ($ million)
  • Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 105: Impact of drivers and challenges in 2023 and 2028
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 107: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 108: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 109: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 110: Matrix on vendor position and classification
  • 12.3 AbbVie Inc.
  • Exhibit 111: AbbVie Inc. - Overview
  • Exhibit 112: AbbVie Inc. - Product / Service
  • Exhibit 113: AbbVie Inc. - Key news
  • Exhibit 114: AbbVie Inc. - Key offerings
  • 12.4 Amgen Inc.
  • Exhibit 115: Amgen Inc. - Overview
  • Exhibit 116: Amgen Inc. - Product / Service
  • Exhibit 117: Amgen Inc. - Key offerings
  • 12.5 Bristol Myers Squibb Co.
  • Exhibit 118: Bristol Myers Squibb Co. - Overview
  • Exhibit 119: Bristol Myers Squibb Co. - Product / Service
  • Exhibit 120: Bristol Myers Squibb Co. - Key news
  • Exhibit 121: Bristol Myers Squibb Co. - Key offerings
  • 12.6 Eli Lilly and Co.
  • Exhibit 122: Eli Lilly and Co. - Overview
  • Exhibit 123: Eli Lilly and Co. - Product / Service
  • Exhibit 124: Eli Lilly and Co. - Key news
  • Exhibit 125: Eli Lilly and Co. - Key offerings
  • 12.7 F. Hoffmann La Roche Ltd.
  • Exhibit 126: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 127: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 128: F. Hoffmann La Roche Ltd. - Key news
  • Exhibit 129: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 130: F. Hoffmann La Roche Ltd. - Segment focus
  • 12.8 Genor Biopharma Holdings Ltd.
  • Exhibit 131: Genor Biopharma Holdings Ltd. - Overview
  • Exhibit 132: Genor Biopharma Holdings Ltd. - Product / Service
  • Exhibit 133: Genor Biopharma Holdings Ltd. - Key offerings
  • 12.9 Gilead Sciences Inc.
  • Exhibit 134: Gilead Sciences Inc. - Overview
  • Exhibit 135: Gilead Sciences Inc. - Product / Service
  • Exhibit 136: Gilead Sciences Inc. - Key news
  • Exhibit 137: Gilead Sciences Inc. - Key offerings
  • 12.10 Johnson and Johnson
  • Exhibit 138: Johnson and Johnson - Overview
  • Exhibit 139: Johnson and Johnson - Business segments
  • Exhibit 140: Johnson and Johnson - Key news
  • Exhibit 141: Johnson and Johnson - Key offerings
  • Exhibit 142: Johnson and Johnson - Segment focus
  • 12.11 Kangstem Biotech Co. Ltd.
  • Exhibit 143: Kangstem Biotech Co. Ltd. - Overview
  • Exhibit 144: Kangstem Biotech Co. Ltd. - Product / Service
  • Exhibit 145: Kangstem Biotech Co. Ltd. - Key offerings
  • 12.12 Novartis AG
  • Exhibit 146: Novartis AG - Overview
  • Exhibit 147: Novartis AG - Business segments
  • Exhibit 148: Novartis AG - Key offerings
  • Exhibit 149: Novartis AG - Segment focus
  • 12.13 Oryn Therapeutics
  • Exhibit 150: Oryn Therapeutics - Overview
  • Exhibit 151: Oryn Therapeutics - Product / Service
  • Exhibit 152: Oryn Therapeutics - Key offerings
  • 12.14 Pfizer Inc.
  • Exhibit 153: Pfizer Inc. - Overview
  • Exhibit 154: Pfizer Inc. - Product / Service
  • Exhibit 155: Pfizer Inc. - Key news
  • Exhibit 156: Pfizer Inc. - Key offerings
  • 12.15 Sanofi
  • Exhibit 157: Sanofi - Overview
  • Exhibit 158: Sanofi - Business segments
  • Exhibit 159: Sanofi - Key news
  • Exhibit 160: Sanofi - Key offerings
  • Exhibit 161: Sanofi - Segment focus
  • 12.16 Sorrento Therapeutics Inc.
  • Exhibit 162: Sorrento Therapeutics Inc. - Overview
  • Exhibit 163: Sorrento Therapeutics Inc. - Business segments
  • Exhibit 164: Sorrento Therapeutics Inc. - Key offerings
  • Exhibit 165: Sorrento Therapeutics Inc. - Segment focus
  • 12.17 UCB SA
  • Exhibit 166: UCB SA - Overview
  • Exhibit 167: UCB SA - Product / Service
  • Exhibit 168: UCB SA - Key offerings

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 169: Inclusions checklist
  • Exhibit 170: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 171: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 172: Research methodology
  • Exhibit 173: Validation techniques employed for market sizing
  • Exhibit 174: Information sources
  • 13.5 List of abbreviations
  • Exhibit 175: List of abbreviations